Fidia S.p.A. (BIT:FDA)
0.1160
-0.0003 (-0.26%)
At close: Jan 30, 2026
Fidia Employees
Fidia had 140 employees as of June 30, 2025.
Employees
140
Change
n/a
Growth
n/a
Revenue / Employee
€150,929
Profits / Employee
€15,657
Market Cap
1.73M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2025 | 140 | - | - |
| Dec 31, 2024 | 159 | -34 | -17.62% |
| Dec 31, 2023 | 193 | -4 | -2.03% |
| Dec 31, 2022 | 197 | - | - |
| Jun 30, 2020 | 289 | -42 | -12.69% |
| Mar 31, 2020 | 299 | -32 | -9.67% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| EuroGroup Laminations | 3,800 |
| Biesse | 3,723 |
| SIT S.p.A. | 1,873 |
| Tesmec | 926 |
| ILPRA | 399 |
| Clabo | 324 |
| Marzocchi Pompe | 263 |
| OSAI Automation System | 249 |
Fidia News
- 19 hours ago - Lilly's $3.5B manufacturing facility in PA to produce next-gen GLP-1 that promises “even more weight loss” - CNBC
- 1 day ago - Corcept Therapeutics (CORT) Shares Drop After FDA Feedback - GuruFocus
- 1 day ago - Regeneron outlines 18 new Phase III studies and expects four FDA approvals in 2026 while advancing EYLEA HD and DUPIXENT growth - Seeking Alpha
- 1 day ago - Analysts Maintain Bull Case On ResMed Despite Competition Concerns - Benzinga
- 1 day ago - New FDA-Approved Eye Drop Sparks Fresh Competition For LENZ Therapeutics' Drug - Benzinga
- 1 day ago - 5 Stocks Primed for a Turnaround in 2026 - Benzinga
- 1 day ago - Regeneron Posts Lower Eylea Sales Amid Rising Competition, Plans $2 Billion New Factory - Benzinga
- 1 day ago - Corcept Therapeutics (CORT) Stock Falls After FDA Rejects Drug Application - GuruFocus